Inventiva (IVA) has released an update.
Inventiva, a clinical-stage biopharmaceutical company, has announced a share repurchase program following approval at their General Meeting on June 20, 2024, aiming to buy back up to 10% of its capital to improve market liquidity. The repurchase plan, with shares priced at a maximum of 40 euros, will also support employee stock options and other allocations, with a duration of 18 months. Aside from the repurchase initiative, Inventiva continues to progress in its clinical trials, including a pivotal Phase III trial for its leading candidate, lanifibranor, for MASH/NASH treatment.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
